BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• 

  Business

  New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma

  Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.

  April 10, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Government

  Appeals Court Stops Rehiring of Fired Federal Workers, Including From HHS

  The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with its mass layoffs at federal agencies.

  April 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Funding

  Tempest Scrambles for Ways to Bankroll Late-Stage Liver Cancer Asset

  According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

  April 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IN PARTNERSHIP WITH DIA

  Breaking Down Barriers: The Nuanced Approach to Women’s Representation in Medical Research
  

  In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.

  April 10, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Neuroscience

  Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy

  Jefferies analysts predict Annexon’s tanruprubart could be approved by mid-2026.

  April 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  Threat to FDA User Fees Program Could Set US Back 35 Years

  Experts express concern that last week’s unprecedented FDA layoffs will trigger a little-known mechanism that could result in a “disaster” the Trump administration doesn’t see coming.

  April 10, 2025

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Immunology and inflammation

  Amgen’s Uplizna Deepens Response Through 1 Year in Myasthenia Gravis

  Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis.

  April 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Tariffs

  Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All

  Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.

  April 10, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Regulatory

  Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts

  Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by the Trump administration.

  April 10, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• Press Releases

  Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

  April 10, 2025

   · 

  4 min read